News
DERM
6.14
-2.85%
-0.18
H.C. Wainwright Remains a Buy on Journey Medical Corp (DERM)
TipRanks · 4d ago
Weekly Report: what happened at DERM last week (0914-0918)?
Weekly Report · 5d ago
Journey Medical: A Small Pharma With A Large Growth Opportunity
Seeking Alpha · 09/19 14:25
Weekly Report: what happened at DERM last week (0907-0911)?
Weekly Report · 09/14 10:16
Weekly Report: what happened at DERM last week (0831-0904)?
Weekly Report · 09/07 10:10
Weekly Report: what happened at DERM last week (0824-0828)?
Weekly Report · 08/31 10:17
ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy?
NASDAQ · 08/25 15:20
Weekly Report: what happened at DERM last week (0817-0821)?
Weekly Report · 08/24 10:17
Journey Medical’s Earnings Call Signals Breakout Momentum
TipRanks · 08/24 00:18
Top Biotech Gainers: DERM Advances On Emrosi Growth, IOVA Revenue Climbs 66%, CAI Raises Guidance
NASDAQ · 08/20 18:51
Longeveron Appoints Jhaveri As CFO Ahead Of Phase 2b Data; Stock Up
NASDAQ · 08/20 01:16
Journey Medical: Q2 Report Confirms Thesis On Track As Emrosi Launch Gains Traction
Seeking Alpha · 08/19 21:42
Weekly Report: what happened at DERM last week (0810-0814)?
Weekly Report · 08/17 10:18
Journey Medical price target raised to $15 from $12 at B. Riley
TipRanks · 08/17 07:36
Journey Medical Price Target Raised to $15.00/Share From $12.00 by B. Riley Securities
Dow Jones · 08/13 13:26
B. Riley Securities Reiterates Buy on Journey Medical, Raises Price Target to $15
Benzinga · 08/13 13:15
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 08/13 12:05
Analysts Offer Insights on Healthcare Companies: Olympus (OtherOCPNF), Journey Medical Corp (DERM) and Definium Therapeutics (DFTX)
TipRanks · 08/13 11:30
Here's What Key Metrics Tell Us About Journey Medical (DERM) Q2 Earnings
NASDAQ · 08/12 22:30
Journey Medical Non-GAAP EPS of $0.10, revenue of $18.5M beats by $0.13M
Seeking Alpha · 08/12 20:08
More
Webull provides a variety of real-time DERM stock news. You can receive the latest news about Journey Medical Corp through multiple platforms. This information may help you make smarter investment decisions.
About DERM
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.